20/20 Biolabs Inc.

NASDAQ: AIDX · Healthcare · Medical - Care Facilities

PublicHQ Gaithersburg, MD · MontgomeryCIK 0001139685Reports USD

#791 of 1,418 Healthcare companies by revenue62nd-percentile growth

EA Score

30D

FH 45DQ 8GM —SS 26

v0.1 · 55/100 weight · provisional

↑ Piotroski F, revenue growth (YoY) · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

$2.0M

Rev growth YoY (TTM)

+23.5%

Net income (FY)

-$3.7M

Employees

as of 2026-08-24

Market cap

$6.8M

as of 2026-08-24

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$2.0M$2.0M2025

Net income-$3.7M-$3.7M2025

Operating income-$3.3M-$3.3M2025

Total assets$4.1M$4.1M2025

Liabilities$4.2M$4.2M2025

Equity-$19.2k-$19.2k2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is 20/20 Biolabs Inc.’s revenue?

20/20 Biolabs Inc. booked $2.0M in FY2025 revenue, growing 17% year over year — faster than most Healthcare companies we track, at a -182.8% net margin.

Peers · Healthcare

Aeolus Pharmaceuticals, Inc.——Cyclerion Therapeutics, Inc.40D HealthLynked Corp.34D Humacyte, Inc.27D Nutriband Inc.52D Dianthus Therapeutics, Inc.49D

Neighbors

Montgomery →

Lockheed Martin Corporation$75.0B81B+Marriott International, Inc.$26.2B82B+United Therapeutics Corporation$3.2B92A Host Hotels & Resorts, Inc.$6.1B69B AGNC Investment Corp.——Federal Realty Investment Trust$1.3B75B+

Key facts

CEOJonathan Cohen

SectorHealthcare

IndustryMedical - Care Facilities

HeadquartersGaithersburg, MD

ExchangeNASDAQ: AIDX

Employees14

IPO date2026-02-19

Latest filings

8-K2026-08-19 8-K2026-08-17 10-Q2026-08-14 8-K2026-08-05 8-K2026-07-22 8-K2026-07-01 DEF 14A2026-06-23 8-K2026-05-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.